DemeRx is a clinical-stage biopharmaceutical company developing ibogaine-derived therapeutics for substance use disorders and other CNS conditions. Its lead candidate DMX-1001 is an oral noribogaine formulation designed to retain the anti-addiction properties of ibogaine while improving cardiac safety and pharmacokinetic control. The company is launching the first U.S. clinical trial of an ibogaine-derived candidate, advancing a long-controversial psychedelic mechanism into modern clinical development.
Company Info
Funding & Investor Relations
None publicly disclosed; private clinical-stage biopharma.
Upcoming Milestones & Key Dates
First U.S. clinical trial readout of DMX-1001 in Alcohol Use Disorder
FDA Type B meeting on broader DMX-1001 development plan
Clinical Development Pipeline
Recent News
DemeRx is launching the first U.S. clinical trial of an ibogaine-derived drug candidate, marking a pivotal moment for the controversial psychedelic despite a long history of safety concerns and a still-cautious FDA posture.
Leadership Team
Founder and Chief Executive Officer
Careers & Job Openings